Clinical Trial Data

Clinical Trial Change Feed

Daily-detected changes across ClinicalTrials.gov records, structured and labeled by change type. Status changes, protocol amendments, endpoint modifications, enrollment shifts, and new site additions or removals.

Request dataset →
450K+ trials monitored
500+ biotech companies tracked
Daily comparison against ClinicalTrials.gov

Detected this week

Recent changes caught automatically from ClinicalTrials.gov.

Updated Aug 30, 2026

Roche Holding Ltd RHHBY Aug 28
NCT04158648 PHASE3 Endpoint

The primary endpoints for mean and median calculated annualized bleed rate for treated bleeds had their timeframes extended from at least 52 weeks to a median of 156.07 weeks (up to 274 weeks). Additionally, several secondary endpoints related to annualized bleed rates were added, specifically focusing on 'Long-term Efficacy' with extended timeframes. The timeframes for many CATCH questionnaire and safety-related secondary endpoints were also extended, generally from approximately 48 months to approximately 274 weeks. Some secondary endpoints were removed, such as 'Change From Baseline in Body Temperature Over Time', 'Change From Baseline in Diastolic Blood Pressure Over Time', 'Change From Baseline in Pulse Rate Over Time', and 'Change From Baseline in Respiratory Rate Over Time'. New secondary endpoints were added, including 'Number of Participants With at Least One Adverse Events of Changes From Baseline in Vital Signs' and 'Number of Participants With at Least One Shifts in Clinical Laboratory Parameters From Baseline WHO Toxicity Scale Grade 0-2 to Post-baseline Grade 3 or 4'.

AMGEN INC AMGN Aug 29
NCT06088199 PHASE3 Update

Status: ACTIVE_NOT_RECRUITING → COMPLETED

ASTRAZENECA PLC AZN Aug 29
NCT07534592 PHASE1 Update

Number Of Arms: 11 → 13

Detailed Change Tracking Available

Trials change quietly. We don't miss it.

Daily comparison against ClinicalTrials.gov. Endpoint modifications, enrollment shifts, and status change categorized and summarized automatically.

NCT04158648

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors

Completed Phase 3

Roche Holding Ltd RHHBY

Enrollment

73

Primary Completion

2021-10

Detected

Aug 28, 2026

Endpoint modification detected automatically

Secondary endpoint 1 timeframe

− Baseline (Week 1), Weeks 13, 25, 37 and 49, and every 12 weeks thereafter until Study Completion/Discontinuation Visit (up to approximately 48 months)
+ Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and Study completion (SC)/Early discontinuation (ED) (up to approximately 274 weeks)

Secondary endpoint 2 timeframe

− Baseline (Week 1), Weeks 13, 25, 37 and 49, and every 12 weeks thereafter until Study Completion/Discontinuation Visit (up to approximately 48 months)
+ Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)

+ 55 more endpoints modified

AI Summary

The primary endpoints for mean and median calculated annualized bleed rate for treated bleeds had their timeframes extended from at least 52 weeks to a median of 156.07 weeks (up to 274 weeks). Additionally, several secondary endpoints related to annualized bleed rates were added, specifically focusing on 'Long-term Efficacy' with extended timeframes. The timeframes for many CATCH questionnaire and safety-related secondary endpoints were also extended, generally from approximately 48 months to approximately 274 weeks. Some secondary endpoints were removed, such as 'Change From Baseline in Body Temperature Over Time', 'Change From Baseline in Diastolic Blood Pressure Over Time', 'Change From Baseline in Pulse Rate Over Time', and 'Change From Baseline in Respiratory Rate Over Time'. New secondary endpoints were added, including 'Number of Participants With at Least One Adverse Events of Changes From Baseline in Vital Signs' and 'Number of Participants With at Least One Shifts in Clinical Laboratory Parameters From Baseline WHO Toxicity Scale Grade 0-2 to Post-baseline Grade 3 or 4'.

Change Detection

What gets caught.

ClinicalTrials.gov logs every update but doesn't surface them. We run a daily comparison and categorize every change.

Endpoint

Endpoint Modifications

Primary and secondary endpoint changes, outcome measures added or removed, assessment timepoints shifted.

Enrollment

Enrollment Changes

Target enrollment updated, eligibility criteria modified, new sites added, age range or inclusion/exclusion criteria changed.

Status

Status Shifts

Recruiting, suspended, terminated, completed. Caught the day the registry updates. Stopped trials flagged immediately.

Study Arm

Study Arms

Arms added or dropped, dosing changes, new intervention branches, comparator updates across multi-arm studies.

Company Pipeline View

Trials organized by company.

Every company mapped to their complete trial pipeline. Trials with recent changes flagged automatically. Sample from Solid Biosciences Inc. (SLDB).

Solid Biosciences Inc. SLDB

4 recruiting
1 Phase 3
6 trials shown
Phase 3 ● Recruiting Endpoint change

A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT...

NCT07160634 · 80 enrolled

Phase 1/2 ● Recruiting

A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

NCT06138639 · 60 enrolled

Phase 1 ● Recruiting

A Study of SGT-212 Gene Therapy in Friedreich's Ataxia

NCT07180355 · 10 enrolled

Phase 1 ● Recruiting

A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (...

NCT07148089 · 18 enrolled

Use Cases

Who Uses This Data

Structured for direct analysis. No cleaning, no manual joins required.

CROs and Site Networks

  • ● Monitor when competing trials open new sites in your geography
  • ● Track trial status changes that signal patient pool availability or competitive pressure
  • ● Identify trial activity by disease or intervention type

Pharma Business Development

  • ● Track competitor pipeline changes that signal strategic pivots or program setbacks
  • ● Monitor endpoint modifications as early signals of program direction
  • ● Map the active trials to identify collaborators or competition in your disease or intervention area

What's Included

Delivery and Data Fields

How It's Delivered

    Source cadence: Daily sync from ClinicalTrials.gov via AACT (3:30am UTC)

    Primary Sources

    • • ClinicalTrials.gov via AACT (NIH/NLM)
    • • Registered trial records
    • • Daily change detection across all registered sponsors

    Fields Include

    • • NCT ID and trial title
    • • Change category (status, endpoint, enrollment, site, arm, date)
    • • Previous and current field values
    • • Change detection date
    • • Sponsor name and canonical company identifier
    • • Phase and MeSH condition codes
    • • Reported enrollment count (before/after where applicable)
    • • Primary completion and study completion dates
    • • AI-generated summaries of endpoint modifications

    Get the Data

    or email [email protected]